The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.
2011
DOI: 10.2119/molmed.2011.00058
|View full text |Cite
|
Sign up to set email alerts
|

Inhibition of HDAC Activity by ITF2357 Ameliorates Joint Inflammation and Prevents Cartilage and Bone Destruction in Experimental Arthritis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
53
0
1

Year Published

2011
2011
2018
2018

Publication Types

Select...
5
3

Relationship

1
7

Authors

Journals

citations
Cited by 91 publications
(57 citation statements)
references
References 40 publications
3
53
0
1
Order By: Relevance
“…These dose-dependent effects of panobinostat closely resemble the effects of butyrate, suggesting that a similar mechanism is involved. Addition of givinostat, which is a well-known pan-HDAC inhibitor that was reported to have beneficial effects in several forms of arthritis in vivo,15 16 decreased LPS-induced IL-1β at 25 nM. This is consistent with a previous study in human PBMCs 24.…”
Section: Discussionsupporting
confidence: 90%
See 1 more Smart Citation
“…These dose-dependent effects of panobinostat closely resemble the effects of butyrate, suggesting that a similar mechanism is involved. Addition of givinostat, which is a well-known pan-HDAC inhibitor that was reported to have beneficial effects in several forms of arthritis in vivo,15 16 decreased LPS-induced IL-1β at 25 nM. This is consistent with a previous study in human PBMCs 24.…”
Section: Discussionsupporting
confidence: 90%
“…Recently, the synthetic pan-HDAC inhibitor givinostat was shown to have a broad anti-inflammatory activity with beneficial effects in experimental models of arthritis and even led to attenuation of clinical scores in a trial with patients with juvenile idiopathic arthritis 15 16. Inhibition of HDACs might therefore also have beneficial effects in acute gouty arthritis.…”
Section: Introductionmentioning
confidence: 99%
“…HDAC inhibitors are the best studied epigenetic therapeutic agents and have been proven to reduce the levels of proinflammatory cytokines (Leoni et al 2005) (Leoni et al 2002). Beneficial effects of HDAC inhibitors have been initially described in animal models of arthritis (Nishida et al 2004) (Lin et al 2007) (Nasu et al 2008) (Saouaf et al 2009) (Joosten et al 2011). In humans 18 HDACs have been described and further characterized (Wang et al 2009b).…”
Section: Gene Expression Genomes and Chromatin Organizationmentioning
confidence: 99%
“…It results in reduced cartilage destruction, bone breakdown, joint swelling and pro-inflammatory cytokine expression by synovial cells and tissue. Furthermore, it reduced the total number of cells arriving at the inflamed joint [60]. More recently, a clinical trial of this agent in systemiconset idiopathic juvenile arthritis resulted in reduced numbers of leucocytes, fewer active arthritic joints and reduced expression of inflammatory cytokines, while remaining safe and beneficial for the patient [61].…”
Section: Histone Acetylation In Ra Murine Models and Human Arthritic mentioning
confidence: 99%